164 related articles for article (PubMed ID: 27496090)
1. Leukocyte adhesion molecule dynamics after Natalizumab withdrawal in Multiple Sclerosis.
Cobo-Calvo Á; Figueras A; Bau L; Matas E; Mañé Martínez MA; León I; Majòs C; Romero-Pinel L; Martínez-Yélamos S
Clin Immunol; 2016 Oct; 171():18-24. PubMed ID: 27496090
[TBL] [Abstract][Full Text] [Related]
2. Natalizumab treatment alters the expression of T-cell trafficking marker LFA-1 α-chain (CD11a) in MS patients.
Jilek S; Mathias A; Canales M; Lysandropoulos A; Pantaleo G; Schluep M; Du Pasquier RA
Mult Scler; 2014 Jun; 20(7):837-42. PubMed ID: 24258149
[TBL] [Abstract][Full Text] [Related]
3. Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells.
Spadaro M; Caldano M; Marnetto F; Lugaresi A; Bertolotto A
J Neuroinflammation; 2015 Aug; 12():146. PubMed ID: 26259673
[TBL] [Abstract][Full Text] [Related]
4. In vitro VLA-4 blockade results in an impaired NK cell-mediated immune surveillance against melanoma.
Gandoglia I; Ivaldi F; Carrega P; Armentani E; Ferlazzo G; Mancardi G; Kerlero de Rosbo N; Uccelli A; Laroni A
Immunol Lett; 2017 Jan; 181():109-115. PubMed ID: 27919749
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of integrin expression on monocytes in multiple sclerosis patients treated with natalizumab.
Dallari S; Franciotta D; Carluccio S; Signorini L; Gastaldi M; Colombo E; Bergamaschi R; Elia F; Villani S; Ferrante P; Delbue S
J Neuroimmunol; 2015 Oct; 287():76-9. PubMed ID: 26439965
[TBL] [Abstract][Full Text] [Related]
6. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.
Stüve O; Marra CM; Bar-Or A; Niino M; Cravens PD; Cepok S; Frohman EM; Phillips JT; Arendt G; Jerome KR; Cook L; Grand'Maison F; Hemmer B; Monson NL; Racke MK
Arch Neurol; 2006 Oct; 63(10):1383-7. PubMed ID: 17030653
[TBL] [Abstract][Full Text] [Related]
7. Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis.
Frisell T; Forsberg L; Nordin N; Kiesel C; Alfredsson L; Askling J; Hillert J; Olsson T; Piehl F
Mult Scler; 2016 Jan; 22(1):85-93. PubMed ID: 25921036
[TBL] [Abstract][Full Text] [Related]
8. Effect of natalizumab treatment on circulating plasmacytoid dendritic cells: a cross-sectional observational study in patients with multiple sclerosis.
Kivisäkk P; Francois K; Mbianda J; Gandhi R; Weiner HL; Khoury SJ
PLoS One; 2014; 9(7):e103716. PubMed ID: 25075741
[TBL] [Abstract][Full Text] [Related]
9. A multicenter, non-interventional study to evaluate the disease activity in Multiple Sclerosis after withdrawal of Natalizumab in Portugal.
Ladeira F; Braz L; Salgado P; Vaz S; Leitão L; Félix C; Correia AS; Silva AMD; Salgado V; Ferreira F; Vale J; Sá MJ; Capela C
Clin Neurol Neurosurg; 2019 Sep; 184():105390. PubMed ID: 31306895
[TBL] [Abstract][Full Text] [Related]
10. CD4/CD8 ratio during natalizumab treatment in multiple sclerosis patients.
Carotenuto A; Scalia G; Ausiello F; Moccia M; Russo CV; Saccà F; De Rosa A; Criscuolo C; Del Vecchio L; Brescia Morra V; Lanzillo R
J Neuroimmunol; 2017 Aug; 309():47-50. PubMed ID: 28601287
[TBL] [Abstract][Full Text] [Related]
11. Effects of Natalizumab Therapy on Intrathecal Immunoglobulin G Production Indicate Targeting of Plasmablasts.
Schlüter M; Oswald E; Winklmeier S; Meinl I; Havla J; Eichhorn P; Meinl E; Kümpfel T
Neurol Neuroimmunol Neuroinflamm; 2021 Jul; 8(5):. PubMed ID: 34210800
[TBL] [Abstract][Full Text] [Related]
12. The TCR Repertoire Reconstitution in Multiple Sclerosis: Comparing One-Shot and Continuous Immunosuppressive Therapies.
Amoriello R; Greiff V; Aldinucci A; Bonechi E; Carnasciali A; Peruzzi B; Repice AM; Mariottini A; Saccardi R; Mazzanti B; Massacesi L; Ballerini C
Front Immunol; 2020; 11():559. PubMed ID: 32328061
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and Adverse Events of Use of Natalizumab in a Brazilian Cohort of Patients With Multiple Sclerosis.
Deslandes MQ; Alves PT; Alvarenga MP; Lessa VCC; Camargo S; Alvarenga RMP; Vasconcelos CC
Clin Ther; 2020 Jul; 42(7):1292-1301. PubMed ID: 32593474
[TBL] [Abstract][Full Text] [Related]
14. Natalizumab Promotes Activation of Peripheral Monocytes in Patients With Multiple Sclerosis.
Frisch ES; Häusler D; Weber MS
Neurol Neuroimmunol Neuroinflamm; 2023 Jul; 10(4):. PubMed ID: 37072216
[TBL] [Abstract][Full Text] [Related]
15. Multiple sclerosis and Natalizumab.
Fiore D
Am J Ther; 2007; 14(6):555-60. PubMed ID: 18090880
[TBL] [Abstract][Full Text] [Related]
16. Therapy of highly active pediatric multiple sclerosis.
Huppke P; Huppke B; Ellenberger D; Rostasy K; Hummel H; Stark W; Brück W; Gärtner J
Mult Scler; 2019 Jan; 25(1):72-80. PubMed ID: 28933245
[TBL] [Abstract][Full Text] [Related]
17. [Natalizumab treatment in multiple sclerosis].
Tanaka M
Rinsho Shinkeigaku; 2015; 55(8):537-43. PubMed ID: 26156254
[TBL] [Abstract][Full Text] [Related]
18. Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis.
Gueguen A; Roux P; Deschamps R; Moulignier A; Bensa C; Savatovsky J; Heran F; Gout O
J Neurol Neurosurg Psychiatry; 2014 Sep; 85(9):1038-40. PubMed ID: 24876183
[TBL] [Abstract][Full Text] [Related]
19. Characterization of naïve, memory and effector T cells in progressive multiple sclerosis.
Nielsen BR; Ratzer R; Börnsen L; von Essen MR; Christensen JR; Sellebjerg F
J Neuroimmunol; 2017 Sep; 310():17-25. PubMed ID: 28778440
[TBL] [Abstract][Full Text] [Related]
20. Prevention of rebound effect after natalizumab withdrawal in multiple sclerosis. Study of two high-dose methylprednisolone schedules.
Fuentes-Rumí L; Hernández-Clares R; Carreón-Guarnizo E; Valero-López G; Iniesta-Martinez F; Cabrera-Maqueda JM; León-Hernández A; Zamarro-Parra J; Morales-Ortiz A; Meca-Lallana JE
Mult Scler Relat Disord; 2020 Sep; 44():102311. PubMed ID: 32593958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
